CASE STUDY 06 / 06
Febuxostat solid dispersions
Ungur et al., Journal of Pharmacy and Pharmacology 2026, 78, rgag019
27 → 134µg/mL
Challenge
Solubility and dissolution behavior may remain challenging even after identifying alternative solid forms.
Scientific approach
A 2026 study examined febuxostat salts and a cocrystal alongside PEG6000-based amorphous solid dispersions, including dissolution and in vitro biological tests.
Published findings
The reported Tos1 salt increased solubility from 27 ± 2 to 100 ± 2 micrograms/mL in water; its PEG6000 dispersion reached 134 ± 2 micrograms/mL under the study conditions.
Development relevance
This research illustrates how solid-form engineering and formulation-oriented investigations may be combined; the measurements are study-specific, not a commercial performance guarantee.
Source
Ungur et al., Journal of Pharmacy and Pharmacology 2026, 78, rgag019; DOI 10.1093/jpp/rgag019.